English

RLS Global AB (publ) Interim Report, Q3, 2022

Report this content

JULY 1st – SEPTEMBER 30th (Previous year in brackets)

  • Net sales amounted to TSEK 198 (TSEK 132).
  • Earnings before interest and taxes (EBIT) amounted to MSEK -5,2 (MSEK 6,2).
  • Earnings per share after dilution at SEK -0,07 (SEK 0,09).
  • Cash flow from operating activities amounted to TSEK -5 114 (TSEK -6 214).
  • Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
  • Equity ratio was 77 % (86 %).

 

JANUARY 1st–SEPTEMBER 30th (Previous year in brackets)

  • Net sales amounted to TSEK 904 (TSEK 472).
  • Earnings before interest and taxes (EBIT) amounted to MSEK -16,4 (MSEK 3,98).
  • Earnings per share after dilution at SEK -0,23 (SEK 0,06).
  • Cash flow from operating activities amounted to MSEK -12,7 (MSEK -3,46).
  • Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
  • Equity ratio was 77 % (86 %).

 

Summary of events during third quarter

  • RLS issues new shares by way of set-off, totaling TSEK 10 000.
  • An article regarding ChloraSolv is published in Journal of Wound Care.

 

Summary of events after third quarteR

  • New CEO Björn Larsson starts October 1.
  • RLS has raised liquid assets through a new issue in November 2022 (rights issue) of MSEK 29.4.
  • The Swedish Medicines Agency has approved RLS’ application for pressure ulcers.
  • RLS visits the conference Wounds UK in Harrogate, England.

 

The Interim Report Q3, 2022, is enclosed and is also available here.

Publication
This information was submitted for publication through the agency of the below contact person, at 08.00 CET on November 24, 2022.

TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. During the period 2012–2017, the company was listed on Aktietorget.

FOR MORE INFORMATION, PLEASE CONTACT:
Björn Larsson, CEO, RLS Global
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25

Eva Jagenheim, CFO, RLS Global
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57

ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global

Subscribe

Documents & Links